Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 1/2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3

Conditions

Lung Neoplasms 29Ovarian Neoplasms 27Fallopian Tube Neoplasms 24Carcinoma, Non-Small-Cell Lung 23Colorectal Neoplasms 16Melanoma 12Carcinoma, Renal Cell 12Carcinoma, Hepatocellular 12Squamous Cell Carcinoma of Head and Neck 11Pancreatic Neoplasms 11Glioblastoma 11Breast Neoplasms 11Triple Negative Breast Neoplasms 10Urinary Bladder Neoplasms 8Prostatic Neoplasms 8Neoplasm Metastasis 8Uterine Cervical Neoplasms 7Brenner Tumor 7Mycosis Fungoides 6Colonic Neoplasms 6Brain Neoplasms 6Rectal Neoplasms 5Multiple Myeloma 5Lymphoma, T-Cell, Cutaneous 5Endometrial Neoplasms 5Sezary Syndrome 4Sarcoma 4Neoplasms 4Nasopharyngeal Carcinoma 4Lymphoma, Large B-Cell, Diffuse 4

Interventions

Cisplatin 56Radiotherapy 34Radiotherapy, Intensity-Modulated 28Magnetic Resonance Spectroscopy 24Radiation 20Carboplatin 19pembrolizumab 17Specimen Handling 16Platinum 141,2-diaminocyclohexaneplatinum II citrate 14Paclitaxel 13Cetuximab 13Fluorouracil 10Surgical Procedures, Operative 9Docetaxel 9Biopsy 9Taxes 8Chemoradiotherapy 8Nivolumab 7Fluorodeoxyglucose F18 7Drug Therapy 7durvalumab 6Surveys and Questionnaires 6fludarabine 5X-Rays 5Observation 5Cyclophosphamide 5aldesleukin 4Standard of Care 4Radiosurgery 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Oropharyngeal Neoplasms × Immunoglobulin G × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03258554 2026-06-02

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 2/3 Completed
196 enrolled 31 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03618134 2023-11-18

Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner

Jonsson Comprehensive Cancer Center

Phase 1/2 Terminated
19 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡